RU2451506C1 - Комбинация для лечения сахарного диабета и его осложнений - Google Patents

Комбинация для лечения сахарного диабета и его осложнений Download PDF

Info

Publication number
RU2451506C1
RU2451506C1 RU2011122374/15A RU2011122374A RU2451506C1 RU 2451506 C1 RU2451506 C1 RU 2451506C1 RU 2011122374/15 A RU2011122374/15 A RU 2011122374/15A RU 2011122374 A RU2011122374 A RU 2011122374A RU 2451506 C1 RU2451506 C1 RU 2451506C1
Authority
RU
Russia
Prior art keywords
combination
diabetes
metformin
combination according
mixture
Prior art date
Application number
RU2011122374/15A
Other languages
English (en)
Russian (ru)
Inventor
Сергей Юрьевич Лешков (RU)
Сергей Юрьевич Лешков
Нина Сергеевна Вихриева (RU)
Нина Сергеевна Вихриева
Сергей Петрович Кречетов (RU)
Сергей Петрович Кречетов
Original Assignee
Сергей Юрьевич Лешков
Нина Сергеевна Вихриева
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сергей Юрьевич Лешков, Нина Сергеевна Вихриева filed Critical Сергей Юрьевич Лешков
Priority to RU2011122374/15A priority Critical patent/RU2451506C1/ru
Priority to EP12738248.9A priority patent/EP2714022A1/en
Priority to EA201301308A priority patent/EA028394B1/ru
Priority to PCT/RU2012/000254 priority patent/WO2012166008A1/en
Priority to JP2014513476A priority patent/JP2014527506A/ja
Priority to KR1020137032709A priority patent/KR101567660B1/ko
Priority to CN2012800085850A priority patent/CN103402506A/zh
Application granted granted Critical
Publication of RU2451506C1 publication Critical patent/RU2451506C1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Medical Informatics (AREA)
  • Obesity (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2011122374/15A 2011-06-02 2011-06-02 Комбинация для лечения сахарного диабета и его осложнений RU2451506C1 (ru)

Priority Applications (7)

Application Number Priority Date Filing Date Title
RU2011122374/15A RU2451506C1 (ru) 2011-06-02 2011-06-02 Комбинация для лечения сахарного диабета и его осложнений
EP12738248.9A EP2714022A1 (en) 2011-06-02 2012-04-05 Combination for treatment of diabetes mellitus
EA201301308A EA028394B1 (ru) 2011-06-02 2012-04-05 Комбинация для лечения сахарного диабета
PCT/RU2012/000254 WO2012166008A1 (en) 2011-06-02 2012-04-05 Combination for treatment of diabetes mellitus
JP2014513476A JP2014527506A (ja) 2011-06-02 2012-04-05 糖尿病治療のための組み合わせ
KR1020137032709A KR101567660B1 (ko) 2011-06-02 2012-04-05 진성 당뇨병을 치료하기 위한 병용제
CN2012800085850A CN103402506A (zh) 2011-06-02 2012-04-05 用于治疗糖尿病的组合

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2011122374/15A RU2451506C1 (ru) 2011-06-02 2011-06-02 Комбинация для лечения сахарного диабета и его осложнений

Publications (1)

Publication Number Publication Date
RU2451506C1 true RU2451506C1 (ru) 2012-05-27

Family

ID=46231593

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011122374/15A RU2451506C1 (ru) 2011-06-02 2011-06-02 Комбинация для лечения сахарного диабета и его осложнений

Country Status (7)

Country Link
EP (1) EP2714022A1 (ko)
JP (1) JP2014527506A (ko)
KR (1) KR101567660B1 (ko)
CN (1) CN103402506A (ko)
EA (1) EA028394B1 (ko)
RU (1) RU2451506C1 (ko)
WO (1) WO2012166008A1 (ko)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2548731C2 (ru) * 2012-10-24 2015-04-20 Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Новосибирский Государственный Педагогический Университет" Средство и способ комплексной терапии больных сахарным диабетом
RU2687256C1 (ru) * 2018-03-26 2019-05-08 Федеральное Государственное бюджетное образовательное учреждение высшего образования Дагестанский государственный медицинский университет Министерства здравоохранения Российской Федерации Даггосмедуниверситет Способ персонализированного лечения хронической болезни почек у больных с диабетической нефропатией
RU2759903C2 (ru) * 2017-02-16 2021-11-18 Вальбьотис Фармацевтический активный ингредиент и его применение, в частности для предупреждения и лечения метаболических расстройств у людей и животных

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2912881A1 (en) 2013-05-24 2014-11-27 Otsuka Pharmaceutical Co., Ltd. Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
US10442610B2 (en) 2014-03-11 2019-10-15 Starbucks Corporation Pod-based restrictors and methods
CN105902761A (zh) * 2016-06-16 2016-08-31 河南中医学院 一种槐花珍在制备治疗高血糖和糖尿病药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2203050C2 (ru) * 1998-09-15 2003-04-27 Корея Инститьют Оф Сайенс Энд Текнолоджи Биофлавоноиды в качестве агента, снижающего уровень глюкозы в крови
RU2284829C2 (ru) * 2004-12-16 2006-10-10 Пятигорская государственная фармацевтическая академия Антидиабетический сбор

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399658B1 (en) * 1996-12-24 2002-06-04 Sumitomo Pharmaceuticals Co., Ltd. Composition containing ascorbic acid
PT974356E (pt) 1998-07-15 2004-02-27 Merck Sante Sas Comprimidos compreendendo uma combinacao de metformina e de glibenclamida
ITMI20002019A1 (it) 1999-09-17 2002-03-15 Novartis Ag Metodo per il trattemento dei disturbi metabolici, in particolare diabete oppure una malattia oppure una condizione associate con il diabete
JP4719372B2 (ja) * 2000-06-21 2011-07-06 花王株式会社 Ｐｐａｒ依存的遺伝子転写活性化剤
DE60135760D1 (de) * 2000-08-01 2008-10-23 Oryza Oil & Fat Chem Nachtkerzensamenextrakte als inhibitoren der zuckerabsorption und deren herstellungsprozess
JP2003300904A (ja) * 2002-04-05 2003-10-21 National Cardiovascular Center 循環器系障害の進展を抑制する医薬組成物
KR20060121887A (ko) * 2003-09-23 2006-11-29 디에스엠 아이피 어셋츠 비.브이. 진성 당뇨병의 치료 및 예방용 조성물
US20070099826A1 (en) * 2003-10-10 2007-05-03 Norman Wong Treatment of diseases associated with the egr-1 enhancer element
WO2006079056A1 (en) * 2005-01-20 2006-07-27 Stephen Holt Herbal compositions containing hoodia
CA2615118A1 (en) * 2005-07-12 2007-01-18 Daiichi Sankyo Company, Limited Pharmaceutical composition containing ppar.gamma. agonist
JP5246833B2 (ja) * 2005-12-16 2013-07-24 独立行政法人産業技術総合研究所 アディポネクチン産生増強剤
JP5246834B2 (ja) * 2005-12-27 2013-07-24 独立行政法人産業技術総合研究所 アディポネクチン産生強化剤
CN101176786A (zh) * 2006-11-08 2008-05-14 中国科学院上海生命科学研究院 增加胰岛素敏感性的方法和组合物
RU2413528C2 (ru) 2007-01-18 2011-03-10 Открытое Акционерное Общество "Валента Фармацевтика" Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
TW200903710A (en) 2007-07-11 2009-01-16 Promos Technologies Inc Manufacturing method for shallow trench isolation
US20090175973A1 (en) * 2007-09-05 2009-07-09 Nina Vikhrieva Coffee cherry compositions and methods for their use in the treatment of diabetes and diabetes related disorders
CN101250106B (zh) * 2008-03-27 2011-05-18 北京市农林科学院 一种提取绿原酸的方法
JP5054594B2 (ja) * 2008-03-31 2012-10-24 花王株式会社 脂質代謝改善剤
RU2378003C1 (ru) 2008-06-06 2010-01-10 Сергей Юрьевич Лешков Фармацевтическая композиция на основе экстракта зеленой ягоды кофе, способ получения и применения
WO2010048114A1 (en) 2008-10-22 2010-04-29 Metaproteomics, Llc Novel mitochondrial uncoupling methods and compositions for enhancing adipocyte thermogenesis
WO2010089874A1 (ja) * 2009-02-05 2010-08-12 フジッコ株式会社 ＰＰＡＲ－γ発現増強剤、アディポネクチン産生促進剤、ＵＣＰ活性剤およびそれらを用いた医薬品・飲食品
EP2418965B1 (en) * 2009-04-17 2016-06-29 DSM IP Assets B.V. Hydroxytyrosol combinations for enhancing mitochondrial function and energy production.
EP2432320A4 (en) * 2009-05-20 2013-03-06 Nutracryst Therapeutics Private Ltd PHARMACEUTICAL CO-CRYSTALS OF QUERCÉTINE
JP2011063557A (ja) * 2009-09-18 2011-03-31 Lion Corp Ｐｐａｒ活性化剤
ES2356536B1 (es) * 2009-09-23 2012-02-13 Probelte Pharma, Sa Una composición de uso como prebiótico que contiene un extracto de granada y un alimento que incluye dicha composición.
CN101851221B (zh) * 2010-05-27 2012-09-05 东北林业大学 一种从落叶松中制备二氢槲皮素的方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2203050C2 (ru) * 1998-09-15 2003-04-27 Корея Инститьют Оф Сайенс Энд Текнолоджи Биофлавоноиды в качестве агента, снижающего уровень глюкозы в крови
RU2284829C2 (ru) * 2004-12-16 2006-10-10 Пятигорская государственная фармацевтическая академия Антидиабетический сбор

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Kannappan S. et all. Insulin sensitizing action of fenugreek seed polyphenols, quercetin & metformin in a rat model //Indian J. Med. Res. - 2009 Apr, 129(4): 401-8. *
Балаболкин М.И. Диабетология. - М.: Медицина, 2000, стр.534-583. *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2548731C2 (ru) * 2012-10-24 2015-04-20 Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Новосибирский Государственный Педагогический Университет" Средство и способ комплексной терапии больных сахарным диабетом
RU2759903C2 (ru) * 2017-02-16 2021-11-18 Вальбьотис Фармацевтический активный ингредиент и его применение, в частности для предупреждения и лечения метаболических расстройств у людей и животных
RU2687256C1 (ru) * 2018-03-26 2019-05-08 Федеральное Государственное бюджетное образовательное учреждение высшего образования Дагестанский государственный медицинский университет Министерства здравоохранения Российской Федерации Даггосмедуниверситет Способ персонализированного лечения хронической болезни почек у больных с диабетической нефропатией

Also Published As

Publication number Publication date
CN103402506A (zh) 2013-11-20
WO2012166008A1 (en) 2012-12-06
EA201301308A1 (ru) 2014-03-31
EA028394B1 (ru) 2017-11-30
JP2014527506A (ja) 2014-10-16
EP2714022A1 (en) 2014-04-09
KR20140008452A (ko) 2014-01-21
KR101567660B1 (ko) 2015-11-10

Similar Documents

Publication Publication Date Title
JP6141907B2 (ja) 医薬組成物、治療方法及びその使用
White Efficacy and safety of incretin-based therapies: clinical trial data
RU2451506C1 (ru) Комбинация для лечения сахарного диабета и его осложнений
CN101897970A (zh) 用于治疗糖尿病的组合物和方法
BRPI1008560A2 (pt) composição farmacêutica compreendendo um inibidor de sglt2, um inibidor de dpp-iv e opcionalmente um outro agente antidiabético e usos dos mesmos, bem como kit os compreendendo
JP2013540801A (ja) 代謝異常の治療のための組合せ医薬
Gökçay Canpolat et al. Glucose lowering treatment modalities of type 2 diabetes mellitus
CN104349790A (zh) 用于治疗糖尿病的葡萄糖激酶活化剂组合物
Guthrie Evolving therapeutic options for type 2 diabetes mellitus: an overview
CN112316150B (zh) 一种用于预防或治疗代谢或损伤相关疾病的药物组合物
KR20080028415A (ko) ＰＰＡＲγ 애고니스트를 함유하는 의약 조성물
US20180333399A1 (en) Method of improving liver function
CA3022247C (en) Composition for treating diabetic disease
MacEwen et al. Drugs for diabetes: part 8 SGLT2 inhibitors
RU2747985C1 (ru) Твердофазная композиция для коррекции метаболических нарушений при сахарном диабете второго типа
Peters et al. Use of sulfonylurea agents in older diabetic patients
Rosas-Guzman et al. SGLT2 inhibitors in diabetes mellitus treatment
CN104582701A (zh) 减轻体重的方法
CN101897698A (zh) 含有维格列汀和b族维生素的降糖药物组合物及其用途
Labieniec-Watala et al. Mitochondria Function in Diabetes–From Health to Pathology–New Perspectives for Treatment of Diabetes-Driven Disorders
WO2022061962A1 (zh) 一种l型氨基酸转运蛋白抑制剂或拮抗剂有效干预糖尿病的方法
CN1913879B (zh) 用于治疗糖尿病的组合物和制药用途
Madhukar et al. A REVIEW ON ANTIDIABETIC DRUGS (ALLOPATHY)
AU2016206292B2 (en) A method of improving liver function
CN112022862A (zh) 磺酰脲类药物的抗衰老新用途

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20180603